AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-04-03 View volume: 2
Anti-drug antibodies (ADAs) are immune responses mounted by patients against biotherapeutic drugs. Detecting and characterizing ADAs is a critical component of immunogenicity assessment in preclinical and clinical development. This guide explains what ADAs are, why they matter, and how immunogenicity is tested.
An ADA is any antibody produced by a patient’s immune system that recognizes and binds to a biotherapeutic drug (monoclonal antibody, Fc-fusion protein, enzyme replacement therapy, etc.) as a foreign antigen. ADAs can be directed against the variable region (anti-idiotypic), the constant region, or non-human framework sequences of the drug molecule.
Reduced Efficacy: ADAs can neutralize the drug by blocking its target-binding site, or accelerate drug clearance by forming immune complexes, reducing drug exposure and therapeutic benefit.
Safety Risks: ADA-drug immune complexes can cause infusion reactions, anaphylaxis, or serum sickness. In rare cases, ADAs cross-react with endogenous counterparts (e.g., anti-EPO ADAs causing pure red cell aplasia).
Regulatory Requirement: FDA, EMA, and NMPA all require immunogenicity assessment as part of biotherapeutic drug development. ADA testing is mandatory in preclinical and clinical programs.
Immunogenicity testing follows a tiered approach recommended by regulatory guidelines:
Tier 1 — Screening: Bridging ELISA or ECL-based assay detects any antibody binding to the drug. Sensitive but not specific — produces both true positives and false positives.
Tier 2 — Confirmatory: Samples that screen positive are re-tested with drug competition. True ADAs show signal reduction when excess drug is added; false positives do not.
Tier 3 — Neutralization: Confirmed ADA-positive samples are tested for neutralizing activity (NAb) using cell-based or competitive ligand-binding assays. NAbs directly block drug function and have the greatest clinical impact.
ADA assay development requires several critical reagents: the drug itself (as capture and detection reagent in bridging format), positive control ADA (anti-drug antibody, typically polyclonal or monoclonal), drug tolerance controls, and negative control serum matrix. AtaGenix provides custom ADA antibody development (polyclonal and monoclonal) as well as ready-to-use PK/ADA assay kits with capture/detection antibodies, calibrators, and QC controls.
Need ADA reagents or PK/ADA assay kits for your biotherapeutic program? AtaGenix provides custom anti-drug antibody development and validated bioanalytical kits in ELISA and MSD formats.
Talk to Technical SupportResponse within 24 hours
Contact Us
+86-27-6552-3339
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
